Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Selects Duke as Site for HCV Drug Trial

Premium

Benitec Biopharma announced last week that it has selected the Duke Clinical Research Unit as a site for its upcoming phase I/II trial for the expressed RNAi-based hepatitis C infection treatment TT-034.

The trial is designed to evaluate single escalating doses of the drug in patients with chronic HCV genotype I infection who have failed previous treatment, Benitec said.

It is expected to enroll 14 patients in five sequential dose cohorts, with the possibility of additional cohorts added to confirm study findings. Endpoints include safety, as well as serum viral load reduction and hepatocyte transduction levels.

Patient enrollment is expected to begin in the second half of the year.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.